Sverige - svenska - Läkemedelsverket (Medical Products Agency)

krka d.d., novo mesto - milbemycinoxim; prazikvantel - tuggtablett - 12,5 mg/125 mg - laktosmonohydrat hjälpämne; milbemycinoxim 12,5 mg aktiv substans; prazikvantel 125 mg aktiv substans - hund

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

krka d.d., novo mesto - milbemycinoxim; prazikvantel - filmdragerad tablett - 16 mg/40 mg - milbemycinoxim 16 mg aktiv substans; prazikvantel 40 mg aktiv substans; laktosmonohydrat hjälpämne; propylenglykol hjälpämne - katt

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

krka d.d., novo mesto - milbemycinoxim; prazikvantel - tuggtablett - 2,5 mg/25 mg - milbemycinoxim 2,5 mg aktiv substans; prazikvantel 25 mg aktiv substans; laktosmonohydrat hjälpämne - hund

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

krka d.d., novo mesto - milbemycinoxim; prazikvantel - filmdragerad tablett - 4 mg/10 mg - milbemycinoxim 4 mg aktiv substans; laktosmonohydrat hjälpämne; propylenglykol hjälpämne; prazikvantel 10 mg aktiv substans - katt

Europeiska unionen - svenska - EMA (European Medicines Agency)

blueprint medicines (netherlands) b.v. - avapritinib - gastrointestinala stromaltumörer - andra antineoplastiska medel, protein kinas-hämmare - ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation.

Europeiska unionen - svenska - EMA (European Medicines Agency)

koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastiska medel - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patienter som har en låg eller mycket låg risk för återfall bör inte få adjuvant behandling. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. förutom vid nyligen diagnostiserad kml kronisk fas, det finns inga kontrollerade studier som visar på en klinisk nytta eller ökad överlevnad för dessa sjukdomar.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

krka d.d., novo mesto - milbemycinoxim; prazikvantel - filmdragerad tablett - 2,5 mg/25 mg - prazikvantel 25 mg aktiv substans; milbemycinoxim 2,5 mg aktiv substans; propylenglykol hjälpämne; laktosmonohydrat hjälpämne - hund

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

krka d.d., novo mesto - milbemycinoxim; prazikvantel - filmdragerad tablett - 12,5 mg/125 mg - laktosmonohydrat hjälpämne; prazikvantel 125 mg aktiv substans; milbemycinoxim 12,5 mg aktiv substans; propylenglykol hjälpämne - hund

Europeiska unionen - svenska - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatid - osteoporosis; osteoporosis, postmenopausal - calciumhomeostas - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

svenska Örtmedicinska institutet ab - echinacea purpurea (röd solhatt) torkad rot; tjockt extrakt (1,3-3,7:1); etanol 55 %; eleutherococcus senticosus (rysk rot) torkat rot; tjockt extrakt (8-15:1); etanol 70 %; justicia adhatoda (malabarnöt) torkat blad; tjockt extrakt (1,7-2,6:1); vatten - oral lösning - sorbitol hjälpämne; propylparahydroxibensoat hjälpämne; metylparahydroxibensoat hjälpämne; eleutherococcus senticosus (rysk rot) torkat rot; tjockt extrakt (8-15:1); etanol 70 % 4,5 mg aktiv substans; echinacea purpurea (röd solhatt) torkad rot; tjockt extrakt (1,3-3,7:1); etanol 55 % 18 mg aktiv substans; justicia adhatoda (malabarnöt) torkat blad; tjockt extrakt (1,7-2,6:1); vatten 27 mg aktiv substans; kaliumsorbat hjälpämne; natriumbensoat hjälpämne